Kornimate/medical-research-clean huggingface dataset:
the influence of antiphospholipid antibodies on the relationship between hyperurecemia, gout and metabolic syndrome

Conditions: Antiphospholipid Syndrome; Endothelial Dysfunction; Hyperuricemia; Gout; Metabolic Syndrome

Summary: patients with hyperuricemia were confirmed to have higher risks of cardiovascular disease, but the exact mechanism remained to be elucidated. many connective tissue diseases such as rheumatoid arthritis are often associated with antiphospholipid antibodies-associated endothelial impairment. in the present study, the investigators will analyze the presence of antiphospholipid antibodies in the serum of the patients with gout/asymptomatic hyperuricemia, with a comparison to the patients of osteoarthritis but without hyperuricemia and gout. the investigators expect to find a correlation between these pathogenic antibody and those cardiovascular co-morbidities.

patients with hyperuricemia were confirmed to have higher risks of cardiovascular disease, but the exact mechanism remained to be elucidated. many connective tissue diseases such as rheumatoid arthritis are often associated with antiphospholipid antibodies-associated endothelial impairment. in the present study, we'll analyze the presence of antiphospholipid antibodies in the serum of the patients with gout/ asymptomatic hyperuricemia, with a comparison to the patients of osteoarthritis but without hyperuricemia and gout. we expect to find a correlation between these pathogenic antibody and those cardiovascular co-morbidities. patient eligibility： 1. patients with gout 2. patients with asymptomatic hyperuricemia 3. patients of osteoarthritis but without hyperuricemia and gout exclusion criteria： patients younger than 20 years old

Eligibility criteria:
inclusion criteria: 1. patient with gouty arthritis 2. patient with asymptomatic hyperurecemia 3. patient of osteoarthritis but without hyperuricemia and gout exclusion criteria: 1.patient younger than 20 y/o.

Keywords: antiphospholipid syndrome gouty arthritis hyperuricemia metabolic syndrome osteoarthritis cardiovascular co-morbidities
covid-19 vaccines in patients with chronic liver disease

Conditions: Liver Disease Chronic

Summary: severe acute respiratory syndrome coronavirus 2 (sars-cov-2) has caused pandemic since outbreak in 2020.patients with chronic liver disease (cld) are at higher risk of mortality and morbidity due to covid-19. despite there is a large number of clinical trials of covid-19 vaccines, only a few participants with chronic liver diseases were included.

this study is a prospective, open-label clinical trial. a total of 300 patients with different cancers including chronic hepatitis, cirrhosis .all of the patients will further accept 18 months follow-up study after vaccination. safety and immunogenicity will be carefully recorded and detected.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * serum alt and ast are both ≤ 80 u/l. * hiv and tpha screening were negative. * body temperature ≤37.0℃. exclusion criteria: * patients who confirmed the diagnosis of liver cancer by imaging examination (ct/mri/b scan). * patients who are allergic to any component of the vaccine, or have a serious history of vaccine allergy. * women who is pregnant, breastfeeding, or planning to be pregnant within 6 months. * patients with cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, and severe hypertension can not be well controlled by drugs. * patients with severe chronic diseases or diseases can not be controlled well during the progress, such as asthma, diabetes, thyroid disease, etc. congenital or acquired angioedema / neuroedema.c. * patients with urticaria within a year. * patients with coagulation disorder. * faintng during acupuncture treatment . * patients who received other investigational drugs within one month. * be receiving anti-tb treatment. * other conditions determined by the researcher.

Keywords: liver disease chronic covid-19 vaccination
using fmri to determine if cerebral hemodynamic responses to pain change following thoracic spine manipulation in individuals with mechanical neck pain

Conditions: Neck Pain

Summary: thoracic spine thrust manipulation (tsm) has been shown to be an effective intervention in the management of patients with neck pain. however the mechanisms for pain relief associated with this intervention remain largely unexplained. recent evidence suggests structures within the brain may have a role in creating responses of pain relief. this study aims to use functional magnetic resonance imaging (fmri) to determine if there is a change in blood flow to structures within the brain following tsm in patients with neck pain. all patients will undergo fmri while receiving painful stimuli directed to two separate sites, the cuticle of the index finger and the great toe. subjects will then receive either tsm or sham-manipulation and then immediately undergo a second fmri scan receiving the same painful stimuli. the primary outcome of interest is the shift in blood flow within the brain before and after tsm or sham manipulation as measured by blood oxygen level dependent (bold) technology. this study will be the first to examine this type of response to manual therapy within the brain in patients with neck pain.


Eligibility criteria:
inclusion criteria: * primary complaint of mechanical neck pain of less than 6 weeks in duration as identified in the patient's initial physical examination. mechanical neck pain is defined as generalized neck and/or shoulder, peri-scapular pain with symptoms provoked by neck postures, neck movements, or palpation of the cervical musculature exclusion criteria: * any medical red flags suggestive of non-musculoskeletal origin of pain, such as metabolic disorders, osteoporosis, tumor, and/or rheumatoid arthritis * no contraindications to spinal mobilization * no contraindications to mri (claustrophobia, presence of cardiac pacemakers, cochlear implants, metal implants, implanted hearing aids, and previous injuries caused by bullets or shrapnel, pregnancy or thought to be pregnant
bleomycin jet injections in keloids

Conditions: Keloid

Summary: this is a single center, double-blind (patient and investigator), randomized, placebo-controlled study with a split-lesion design, in which selected keloids will receive three consecutive treatments of a) bleomycin and b) placebo (saline (nacl 0,9%)), administered with an electronic pneumatic jet injector.

this is a single center, double-blind (patient and investigator), randomized, placebo-controlled study with a split-lesion design.all study procedures will be performed at the department of dermatology, erasmus mc medical center in patients referred for scar treatment to our outpatient clinic. clinical photos will be obtained after signing the informed consent form by patient and investigator. study visits and clinical assessments will be scheduled at baseline, 4 weeks, 8 weeks, and 12 weeks. measurements include clinical photography, scar volume measured by 3d-camera, posas questionnaire, laser speckle contrast imaging to visualize keloid scar vascularization, measurement of residue formation on the skin, and a treatment related questionnaire. the keloid will be divided into two treatment areas, and randomly assigned to three consecutive treatments of: a) bleomycin and b) placebo (saline (nacl 0,9%)), administered with an electronic pneumatic jet injector.

Eligibility criteria:
inclusion criteria: 1. subject has provided written informed consent; 2. subject is ≥ 18 years of age at time of screening; 3. subject has at least one keloid scar of ≥ 4 cm in length, or two separate keloids with a length of ≥2cm, with a minimum \> 1.0 cm apart in the same anatomical region. 4. subject is willing to fill in questionnaires and take photos using an e-diary application on their phone. exclusion criteria: 1. known hypersensitivity to any component of the test materials; 2. pregnant or breast-feeding women (pregnancy test prior to treatment); 3. previous bleomycin treatment of the keloid within the last 12 weeks prior to screening. 4. non-response to previous bleomycin treatments of the keloid. 5. any medical or psychiatric condition which, in the investigator's opinion, would preclude the participant from adhering to the protocol or completing the study per protocol.

Keywords: keloid dermatology bleomycin jet-injection
leuprolide, bicalutamide, and implant radiation therapy in treating patients with locally recurrent prostate cancer after external-beam radiation therapy

Conditions: Prostate Cancer

Summary: rationale: androgens can cause the growth of prostate cancer cells. antihormone therapy, such as leuprolide and bicalutamide, may lessen the amount of androgens made by the body. implant radiation therapy kills tumor cells by placing material such as radioactive iodine directly into or near a tumor. giving leuprolide and bicalutamide together with implant radiation therapy may kill more tumor cells. purpose: this phase ii trial is studying the side effects of giving leuprolide and bicalutamide together with implant radiation therapy and to see how well it works in treating patients with locally recurrent prostate cancer after external-beam radiation therapy.

objectives: * determine the feasibility and patient tolerance of interstitial brachytherapy combined with androgen-deprivation therapy for patients with locally recurrent prostate cancer after prior external-beam irradiation. * determine the toxicity of interstitial brachytherapy combined with androgen-deprivation therapy in these patients. * determine the tumor response to interstitial brachytherapy combined with androgen-deprivation therapy in these patients. outline: patients receive neoadjuvant therapy comprising leuprolide acetate intramuscularly for 3 months and oral bicalutamide once daily for 30 days, beginning on the first day of leuprolide acetate administration. patients then undergo interstitial brachytherapy implantation with i-125. following brachytherapy, patients receive adjuvant leuprolide acetate every 3 months for an additional 6 months. quality of life is assessed at baseline and at every treatment and follow-up visit. after completion of study therapy, patients are followed every 3 months for 2 years, every to 4-6 months for 3 years, and then annually thereafter.

Eligibility criteria:
disease characteristics: * biopsy-proven adenocarcinoma of the prostate * locally recurrent disease, defined by digital rectal examination and/or rising prostate-specific antigen (psa) * no evidence of nodal or distant metastasis (i.e., n0, m0) on physical examination, bone scan, or ct scan of the pelvis * clinical stage t1c-t3a disease at the time of recurrence * psa \< 10 ng/ml * prostate volume by transrectal ultrasonography \< 60 cc * received prior external beam radiotherapy patient characteristics: * ecog performance status 0-2 * wbc ≥ 3,000/μl * platelet count ≥ 90,000/μl * hemoglobin ≥ 10 g/dl * alkaline phosphatase \< 2 times normal * ast \< 2 times normal * normal prothrombin time and partial thromboplastin time * no significant obstructive urinary symptoms (aua score ≤ 16) * no contraindication for general anesthesia prior concurrent therapy: * see disease characteristics * no prior transurethral resection of the prostate

Keywords: adenocarcinoma of the prostate recurrent prostate cancer stage i prostate cancer stage ii prostate cancer stage iii prostate cancer
a study to evaluate jnj-64565111 pharmacokinetics and safety in adult participants with varying degrees of renal function

Conditions: Kidney Failure, Chronic

Summary: the purpose of study is to evaluate the pharmacokinetics of a single, subcutaneous dose of jnj-64565111 in adult participants with varying degrees of renal function including participants with end stage renal disease, requiring hemodialysis, compared with participants with normal renal function.


Eligibility criteria:
inclusion criteria: * if a woman, must be postmenopausal (no spontaneous menses for at least 2 years), surgically sterile, or if sexually active, be practicing an effective method of birth control before entry and throughout the study * a woman must have a negative highly sensitive serum (beta human chorionic gonadotropin \[hcg\]) at screening. on day -1, female non-end-stage renal disease (esrd) participants should have a negative urine pregnancy test and female esrd participants requiring hemodialysis (hd) should have a negative serum pregnancy test * a woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction (from screening through day 42 postdose) * body mass index (weight \[kilogram {kg}\]/height\^2 \[ meter {m}\]\^2) between 18 and 40 kg/m\^2 (inclusive), and body weight not less than 50 kg * have normal renal function defined as: predicted estimated glomerular filtration rate greater than or equal to (\>=) 90 milliliter (ml)/minute based on the chronic kidney disease-epidemiology formula (for participants with normal renal function) exclusion criteria: * history of, or a reason to believe a participant has a history of, drug or alcohol abuse according to diagnostic and statistical manual of mental disorders (5th edition) (dsm v) criteria within 5 years before screening or positive test result(s) for alcohol and/or drugs of abuse (such as barbiturates, opiates, opioids, cocaine, cannabinoids, amphetamines, and benzodiazepines) at screening and day -1 of the treatment period (unless medically prescribed) * any surgical or medical condition that potentially may alter the absorption, metabolism, or excretion of the study drug, with the exception of renal impairment as described in the inclusion criteria, and except for participants who had a cholecystectomy or a hernia repair * history of clinically significant allergies, especially known hypersensitivity or intolerances * known allergy to jnj-64565111 or its excipients * donated blood or blood products or had substantial loss of blood (more than 500 ml) within 3 months before the first administration of study drug or intention to donate blood or blood products during the study or at least 2 months after the completion of the study
the effect of obesity on venous puncture pain

Conditions: Pain; Cannulation; Body Mass Index

Summary: before surgery, patients will fill the beck anxiety, distress tolerance test and pain katastrophizing test. patients will be divided into two groups according to bmi\> 30kg / m2 (group a) and bmi \<30kg / m2 (group b). compared to body weight, venous vascular pain of the groups will be compared.

seventy patients will be randomized to two groups(bmi\> 30kg / m2 (group a) and bmi \<30kg / m2 (group b) during peripheral venous cannulation (pvc). the patients' visual analog scores will be measured during peripheral venous cannulation.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologist (asa) physical status 1 and 2, between the ages of 18 and 65, were scheduled for elective surgery exclusion criteria: * patients with a history of anxiety disorders or hearing problem and preoperative pain, emergency surgery
a multicenter randomized study of vitamin d combined with hd-dxm versus hd-dxm for the treatment of itp

Conditions: Immune Thrombocytopenia

Summary: the project was undertaking by qilu hospital of shandong university in china. in order to report the efficacy and safety of vitamin d combining with high-dose dexamethasone for the treatment of adults with newly-diagnosed primary immune thrombocytopenia (itp).

the investigators anticipate to undertaking a prospective, multicenter, randomised controlled trial of 60 itp adult patients. one part of the participants are randomly selected to receive vitamin d (given rocaltrol orally at a dose of 0.25 μg per day for 1 month), combining with dexamethasone (given orally at a dose of 40 mg per day for 4 days, two-cycles with an interval of 10 days); the others are selected to receive high-dose of dexamethasone treatment plus placebo. platelet count, bleeding and other symptoms were evaluated before and after treatment. serum calcium and creatinine are monitored. adverse events are also recorded throughout the study. in order to report the efficacy and safety of vitamin d combining with high-dose dexamethasone therapy for the treatment of adults with itp.

Eligibility criteria:
inclusion criteria: 1. corresponding to the diagnostic criteria for immune thrombocytopenia 2. newly diagnosed itp patients 3. to show a platelet count \<30 \* 10\^9/l, and with bleeding manifestations 4. willing and able to sign written informed consent exclusion criteria: 1. suffered from diseases associated with hypercalcemia. 2. vitamin d intoxication 3. received chemotherapy or anticoagulants or other drugs affecting the platelet counts within 3 months before the screening visit; 4. received second-line itp-specific treatments (eg, cyclophosphamide, 6-mercaptopurine, vincristine, vinblastine, etc) within 3 months before the screening visit; 3.received high-dose steroids or ivig in the 3 weeks prior to the start of the study; 5. current hiv infection; 6. severe medical condition (lung, hepatic or renal disorder) other than chronic itp. unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac arrhythmia) 7. female patients who are nursing or pregnant, who may be pregnant, or who contemplate pregnancy during the study period; 8. have a known diagnosis of other autoimmune diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct coombs test; 9. patients who are deemed unsuitable for the study by the investigator.
liver regeneration

Conditions: Liver Diseases; Liver Cancer

Summary: the liver is the only visceral organ with a tremendous capacity to regenerate. we don't yet understand how normal liver regeneration occurs (on a molecular level) or how to distinguish between normal and "abnormal"/neoplastic regeneration. this study will characterize the role of the different liver cell types in the regeneration process and will examine gene expression changes in the various liver cell types.

new studies are demonstrating that rodent models of the liver and liver disease are inadequate. the human liver is quite different and needs to be studied directly. the cell expression of human liver cells during regeneration has many implications for treatment of patients with cirrhosis and cancer. this study will characterize the role of the different liver cell types in the regeneration process and will examine gene expression changes in the various liver cell types. we hypothesize that there is significant crosstalk among hepatocytes, macrophages, and t-cell subsets in the human liver, stimulating the regenerative process. tissue will be obtained from serial biopsies of "healthy" liver that is regenerating in patients who undergo liver resection for metastatic colorectal cancer. all participants must first provide written informed consent and meet study eligibility criteria. the first tissue sample will be collected intraoperatively, then serial fine-needle aspiration biopsies (fnab) will be performed approx. 1 week following surgery, and 1 month following surgery. liver regeneration will also be assessed using routine imaging of the liver at approx. 3 months. retrospective (previously collected diagnostic or biobanked) tissue is also being included for study, given lower than anticipated enrollment.

Eligibility criteria:
inclusion criteria: * willing and able to provide written informed consent * no history of liver disease or dysfunction exclusion criteria: * patients who receive chemotherapy within the 6 weeks prior to their hepatectomy and/or would be started on active chemotherapy within the first 4 weeks post-hepatectomy. * patients requiring long-term anticoagulation
comparison of the effectiveness of oral lactase enzyme and lactose free formula

Conditions: Secondary Lactose Intolerance

Summary: this study aimed to fill the gaps by comparing the effectiveness of oral lactase enzyme and lactose free formula in the management of secondary lactose intolerance in persistent and severe persistent diarrhea.

although it is well understood that oral lactase enzyme can play a pivotal role in hastening recovery due to secondary lactose intolerance in persistent diarrhea, there is limited local data available in this regard. if exogenous oral lactase enzyme is found to be more effective, it would help children receive uninterrupted milk and milk-based diet during the diarrheal episode, as the former would aid digestion and absorption of lactose, thus providing the necessary nutrients especially (calcium) and vitamins so vital in this period of rapid growth.

Eligibility criteria:
inclusion criteria: * both genders * aged 6-24 months * presented with persistent or severe persistent diarrhea due to secondary lactose intolerance * patients on formula or mixed feeding, or formula/cow/buffalo milk exclusion criteria: * severe acute malnutrition * hemodynamic instability (shock) * those on oral antibiotics or on excessive juices * with conditions of malabsorptive states (celiac disease, protein losing enteropathy, or irritable bowel syndrome)
fitt exercise counseling with interactive accelerometry and physical activity in adolescents at increased risk of early cardiovascular disease: a pilot study

Conditions: Coronary Artery Disease Risk High

Summary: this pilot study seeks to compare the change in energy expenditure and fitness levels of patients seen in the children's hospital preventive cardiology program receiving standard of care provider exercise counseling to similar patients receiving frequency, intensity, time, type (fitt) exercise prescription and counseling combined with bodymedia supported by an online interactive tool. the investigators primary hypothesis is that this interactive technology coupled with support from a exercise specialist will increase the energy expenditure of the investigators patients over standard of care provider counseling. the investigators secondary hypotheses include greater improvement in measured physical fitness peak oxygen consumption (vo2max), oxygen consumption (vo2) at anaerobic threshold (at) and ventilation/carbon dioxide (ve/vco2) slope, lipid profiles, blood pressure, arterial stiffness, body mass index (bmi), bmi percentile, and self-efficacy in the intervention group compared to control.


Eligibility criteria:
inclusion criteria: 1. patients at increased risk of atherosclerosis based on lipid profiles (total cholesterol \> 199 mg/dl, high density lipoprotein \ 129 mg/dl, blood pressure (systolic blood pressure or diastolic blood pressure \> 90th percentile), obesity (\>85%body mass index) 2. ages 13-21 years 3. reporting an average of less than 60 minutes per day of moderate to vigorous exercise most (5) days of the week. 4. regular access to the internet with the capacity to download the device 5. commitment on the part of a parent to supervise internet access as part of this protocol exclusion criteria: 1. unable to exercise based on physician recommendations or medical conditions 2. unable/unwilling to complete requirements of the research study including consent and assent. 3. not proficient in english

Keywords: patients at increased risk for atherosclerosis